文献速递泌尿男性生殖肿瘤

SWITCH II:索拉非尼-帕唑帕尼序贯对比帕唑帕尼-索拉非尼序贯治疗晚期或转移性肾细胞癌的III期随机开放标签研究(AUO AN 33/11)

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).
PubMed 文献 · Eur J Cancer · 2018-12-07

这项多中心随机III期研究在未接受过系统治疗的晚期或转移性肾细胞癌患者中比较索拉非尼序贯帕唑帕尼(So-Pa)与帕唑帕尼序贯索拉非尼(Pa-So)的疗效与安全性,共随机377例(So-Pa组189例,Pa-So组188例)。主要终点总无进展生存期(tPFS)中位值So-Pa组8.6个月(95%CI 7.7-10.2) vs Pa-So组12.9个月(95%CI 10.8-15.2),HR 1.36(单侧95%CI上限1.68),未达到预设的HR<1.225非劣效界值。一线PFS和疾病控制率(DCR)的显著差异支持Pa-So序贯,总生存期(OS)和二线PFS无显著差异。

要点

  • So-Pa组中位tPFS 8.6个月 vs Pa-So组12.9个月,HR 1.36,未达到非劣效界值。
  • 一线PFS和DCR显示显著差异,支持Pa-So序贯方案。
  • OS和二线PFS无显著差异,不良反应与已知多激酶抑制剂毒性一致。

核心结论

  • So-Pa序贯方案在主要终点tPFS上未能证明非劣效于Pa-So序贯方案。
  • 一线PFS和DCR的结果支持Pa-So序贯方案。

研究设计与样本

  • 多中心、随机、开放标签III期研究,比较So-Pa与Pa-So序贯治疗未接受过系统治疗的晚期/转移性肾细胞癌患者。
  • 共随机377例患者(So-Pa组189例,Pa-So组188例),计划入组544例,实际入组率低于预期。
  • 给药方案:索拉非尼2×400 mg/天,疾病进展或不耐受毒性后序贯帕唑帕尼1×800 mg/天,或反之。
  • 主要终点为总无进展生存期(tPFS),定义为从随机化至二线治疗期间疾病进展或死亡的时间。

主要发现

  • 中位tPFS:So-Pa组8.6个月(95%CI 7.7-10.2) vs Pa-So组12.9个月(95%CI 10.8-15.2),HR 1.36(单侧95%CI上限1.68),超过预设的非劣效界值HR<1.225。
  • 一线PFS和DCR显示有利于Pa-So组的显著统计学差异。
  • OS和二线PFS无显著统计学差异。
  • 不良反应谱与各自多激酶抑制剂的已知毒性一致,包括腹泻、疲乏、手足皮肤反应和高血压。

关键数值与推荐

  • 非劣效界值预设为单侧95%CI的HR<1.225。
  • So-Pa组中位tPFS 8.6个月(95%CI 7.7-10.2) vs Pa-So组12.9个月(95%CI 10.8-15.2),HR 1.36(单侧95%CI上限1.68)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 计划入组544例,实际入组377例,实际入组率低于预期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This trial compared the sequential therapy with the multikinase inhibitor sorafenib (So) followed by pazopanib (Pa) or vice versa in advanced/metastatic renal cell carcinoma (mRCC) patients. METHODS: This multicenter, randomized phase 3 study assessed the sequential use of So-Pa versus Pa-So in patients with mRCC without prior systemic therapy. Pts were randomized to So 2 × 400 mg/day followed by Pa 1 × 800 mg/day in case of progression or intolerable toxicity or vice versa. Primary endpoint was total PFS (tPFS), defined as time from randomization to progression, or death during second-line therapy. Key secondary endpoints included overall survival (OS), first-line PFS, disease control rate (DCR) and safety. RESULTS: A total of 377 pts were randomized (So-Pa, n = 189; Pa-So, n = 188). Recruitment of a total 544 pts was calculated, but actual accrual rate turned out to be lower than expected. The primary endpoint median tPFS was 8.6 mo (95% CI 7.7-10.2) for So-Pa and 12.9 mo (95% CI 10.8-15.2) for Pa-So with a hazard ratio (HR) of 1.36 (upper limit of one-sided 95% CI 1.68), which exceeded a predefined HR <1.225 as a one-sided 95% confidence interval. Non-inferiority of So-Pa regarding tPFS was not met. Secondary endpoints displayed marked statistical differences in favor of Pa-So in first-line PFS and DCR but not for OS and 2nd-line PFS. Side effect profiles were consistent with known toxicities of the respective multikinase-inhibitor including diarrhea, fatigue, hand-foot skin reaction and hypertension. CONCLUSIONS: Non-inferiority of the primary endpoint tPFS could not be demonstrated for So-Pa. The results for first-line PFS and DCR favored the Pa-So sequence. TRIAL REGISTRATION: NCT01613846, www.clinicaltrials.gov.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Retz M, Bedke J, Bögemann M, et al. SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11). Eur J Cancer. 2018. PMID: 30529901. doi:10.1016/j.ejca.2018.11.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。